Diuretics. II. Clinical considerations.
D000284:Administration, Oral; D000628:Aminophylline / Q000009:adverse effects; D001201:Ascites / Q000188:drug therapy; D002118:Calcium / Q000652:urine; D050260:Carbohydrate Metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects; D003919:Diabetes Insipidus / Q000188:drug therapy; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy; D004976:Ethacrynic Acid / Q000009:adverse effects; D005260:Female; D005665:Furosemide / Q000009:adverse effects; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007008:Hypokalemia / Q000139:chemically induced; D007010:Hyponatremia / Q000139:chemically induced; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000150:complications; D008353:Mannitol / Q000009:adverse effects; D009318:Natriuresis / Q000187:drug effects; D009404:Nephrotic Syndrome / Q000188:drug therapy; D009941:Organomercury Compounds / Q000009:adverse effects / Q000627:therapeutic use; D011041:Poisoning / Q000188:drug therapy; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy; D013148:Spironolactone / Q000009:adverse effects; D014223:Triamterene / Q000009:adverse effects; D014527:Uric Acid / Q000378:metabolism
D002257:Carbonic Anhydrase Inhibitors; D004232:Diuretics; D009941:Organomercury Compounds; D014527:Uric Acid; D013148:Spironolactone; D000628:Aminophylline; D008353:Mannitol; D005665:Furosemide; D004976:Ethacrynic Acid; D002118:Calcium; D014223:Triamterene